Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104280 · ClinicalTrials.gov registry record
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
A clinical trial of Opioid Use Disorder and Sleep Disturbance, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 200
- Enrollment target
- 2
- Study locations
NCT06104280 is a study of Opioid Use Disorder and Sleep Disturbance that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06104280, a study of Opioid Use Disorder and Sleep Disturbance, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.
Conditions Studied
Interventions
- OTHER Post-Illumination Pupillary Response (PIPR)
- OTHER Polysomnography
- OTHER Multiple Sleep Latency Test
- BEHAVIORAL Ecological Momentary Assessments
- DEVICE Actigraphy
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2029-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104280
The ClinicalTrials.gov registry entry for NCT06104280 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (96% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 5 interventions - of which Post-Illumination Pupillary Response (PIPR) is the first listed.
NCT06104280 reports 2 study locations spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06104280 about?
NCT06104280 is a clinical study titled "Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment". Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investiga...
What is the current status of trial NCT06104280?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-01-06. Estimated completion is 2029-01-01.
What conditions does trial NCT06104280 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Sleep Disturbance.
What interventions are being tested in trial NCT06104280?
The interventions under investigation include: Post-Illumination Pupillary Response (PIPR) (OTHER), Polysomnography (OTHER), Multiple Sleep Latency Test (OTHER), Ecological Momentary Assessments (BEHAVIORAL), Actigraphy (DEVICE).
Who is sponsoring clinical trial NCT06104280?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104280 being conducted?
This trial has 2 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.